886206-13-9

Upstream product

• 886206-12-8 C₂₁H₃₃N₃O₃ 
• 353-83-3 1,1,1-trifluoro-2-iodoethane 
• 178671-99-3 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 

Downstream Products

• 959843-37-9 C₁₈H₂₆F₃N₃O 

Relevant academic research and scientific papers

Aminocyclohexylsulfonamides: Discovery of metabolically stable α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) can be effectively treated by α1 adrenergic receptor antagonists, but these drugs also produce side effects that are related to their subtype non-selective nature. To overcome

CYCLOHEXYLDIAMINES AS SELECTIVE ALPHA 1A/1D ADRENORECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATE HYPERTROPHY AND LOWER URINARY TRACT SYMPTOMS

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable form thereof, as dual selective a1a / a 1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.